Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 10/20 | 0.51 |
| ▸ | SCTR | P47872 | 1/20 | 0.51 |
| ▸ | TFPI | P10646 | 1/20 | 0.49 |
| ▸ | GCGR | P47871 | 1/20 | 0.48 |
| ▸ | MC4R | P32245 | 1/20 | 0.47 |
| ▸ | APLNR | P35414 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18116796 | 0.92 | TFPI (0.51) | GLP1RSCTRTFPIMC4RAPLNR | |
| SCHEMBL18388624 | 0.91 | APLNR (0.47) | GLP1RSCTRTFPIMC4RAPLNR | |
| SCHEMBL30519216 | 0.86 | GLP1R (0.46) | GLP1RSCTRAPLNR | |
| SCHEMBL16455571 | 0.86 | TFPI (0.45) | GLP1RSCTRTFPIAPLNR | |
| SCHEMBL29445552 | 0.85 | GLP1R (0.55) | GLP1RSCTRTFPIKEAP1 | |
| SCHEMBL30419550 | 0.85 | GLP1R (0.55) | GLP1RSCTRTFPIKEAP1 | |
| SCHEMBL30605456 | 0.85 | NPY4R (0.52) | GLP1RSCTRAPLNR | |
| SCHEMBL16455229 | 0.83 | GLP1R (0.47) | GLP1RSCTRTFPIAPLNR | |
| SCHEMBL29519652 | 0.83 | NPY4R (0.54) | GLP1RSCTRAPLNR | |
| SCHEMBL15302935 | 0.83 | GLP1R (0.51) | GLP1RSCTRTFPIGCGRMC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10421954-B2 | Hybrid polymers, pharmaceutical compositions and methods of synthesizing the same | NEW YORK UNIVERSITY (US) | 2019-09-24 | — | — | US | disclosed |
| US-20170015991-A1 | HYBRID POLYMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF SYNTHESIZING THE SAME | NEW YORK UNIVERSITY | 2017-01-19 | — | — | US | disclosed |
| US-9458449-B2 | Hybrid polymers, pharmaceutical compositions and methods of synthesizing the same | NEW YORK UNIVERSITY (US) | 2016-10-04 | — | — | US | disclosed |
| US-20150044189-A1 | HYBRID POLYMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF SYNTHESIZING THE SAME | NEW YORK UNIVERSITY | 2015-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10421954-B2 | Hybrid polymers, pharmaceutical compositions and methods of synthesizing the same | F12, RPS4Y1, NPY1R | GLP1R 111/4885SCTR 424/4885TFPI 2247/4885 |
| US-20170015991-A1 | HYBRID POLYMERS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF SYNTHESIZING THE SAME | F12, RPS4Y1, NPY1R | GLP1R 111/4885SCTR 424/4885TFPI 2247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.